



MEMORANDUM OF MEETING

To: Docket No. 2003P-0029/CP1
Date: May 17, 2004
Subject: Phase out of essential use for CFC containing albuterol metered-dose inhalers (MDIs)
Attendees: Daniel E. Troy, FDA Chief Counsel, Lynn Whipkey Mehler, FDA Associate Chief Counsel for Drugs, Tametria Johnson, FDA-CFSAN, Loren Monroe, Barbour Grffith & Rogers Inc., J. Stanley Hull, GlaxoSmithKline (GSK), Janie A. Kinney, GSK, Sarah J. Walsh, GSK, William A. Zoffer, GSK

GSK requested meeting to discuss the phase out of the essential use for CFC containing albuterol MDIs. GSK explained that they believe that all of the criteria set out in 21 CFR 2.125 have been met and explained what GSK is committed to doing to satisfy patient need for treatment of asthma and COPD. FDA encouraged submission of comments after the proposed rule regarding this essential use is published.

2003P-0029

MM 1